F&C Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

F&C Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-41,247	Closed	-$3.12M	–	741
2013 Q4	$3.12M	Hold	41,247	–	–	0.04%	378
2013 Q3	$2.9M	Hold	41,247	–	–	0.04%	401
2013 Q2	$2.4M	Buy	+41,247	New	+$2.38M	0.03%	431

Other funds holding IBB

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

F&C Asset Management's IBB Position: Q1 2014 in Review

F&C Asset Management sold out of iShares Biotechnology ETF (IBB) in Q1 2014, closing a stake of 41,247 shares — an estimated $3.12M sold.

F&C Asset Management first reported a position in IBB in Q2 2013 and held it in 3 quarters. The position peaked at $3.12M in Q4 2013. 288 funds tracked by Wall St. Rank hold IBB as of Q1 2014.

F&C Asset Management reported no remaining iShares Biotechnology ETF position as of Q1 2014 after selling out during the quarter.
F&C Asset Management sold 41,247 iShares Biotechnology ETF shares in Q1 2014, an estimated $3.12M.
F&C Asset Management first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 3 quarters.
F&C Asset Management's iShares Biotechnology ETF position peaked at $3.12M in Q4 2013.
288 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2014.

Based on F&C Asset Management's 13F filing for Q1 2014, filed 14 May 2014.